Drug Interactions between Mepron and rifabutin
This report displays the potential drug interactions for the following 2 drugs:
- Mepron (atovaquone)
- rifabutin
Interactions between your drugs
rifabutin atovaquone
Applies to: rifabutin and Mepron (atovaquone)
GENERALLY AVOID: Coadministration with a rifamycin may decrease the plasma concentrations of atovaquone. The exact mechanism is unknown but may be related to the enzyme-inducing effects of rifamycins. In 13 HIV-infected volunteers, administration of atovaquone suspension (750 mg orally every 12 hours) with rifampin (600 mg orally every 24 hours) resulted in a 52% decrease in the average steady-state plasma atovaquone concentration and a 39% reduction in atovaquone half-life (from 82 hours to 50 hours) compared to administration without rifampin. Similarly, concomitant administration of rifabutin has been shown to reduce atovaquone plasma concentrations by approximately 34%.
MANAGEMENT: The use of atovaquone in combination with rifampin or rifabutin is not recommended. The same precaution may be applicable to rifapentine, although clinical data are lacking.
References (3)
- (2001) "Product Information. Mepron (atovaquone)." Glaxo Wellcome
- Goodwin SD, Fish DN (1995) "Criteria for use of atovaquone oral suspension in adult inpatients and outpatients." Am J Health Syst Pharm, 52, p. 2460-2
- (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
Drug and food interactions
atovaquone food
Applies to: Mepron (atovaquone)
ADJUST DOSING INTERVAL: Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone. In 16 healthy volunteers, administration of a single 750 mg dose of atovaquone suspension following a standard breakfast (23 g fat: 610 kCal) resulted in an approximately 3.4-fold increase in the mean peak plasma concentration (Cmax) and a 2.5-fold increase in the mean area under the plasma concentration-time curve (AUC) of atovaquone compared to administration following an overnight fast. In a study consisting of 19 HIV-infected volunteers receiving atovaquone suspension 500 mg/day, Cmax and AUC of atovaquone increased by 72% and 66%, respectively, in the fed state relative to the fasting state.
MANAGEMENT: To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day. Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.
References (3)
- (2001) "Product Information. Mepron (atovaquone)." Glaxo Wellcome
- (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.